Teva intros erythromycin tablets
Erythromycin oral tablets had a market value of more than $49 million, according to January 2021 IQVIA data.
Teva is offering generic erythromycin tablets in dosage strengths of 250 mg and 500 mg.
It is indicated to treat a variety of bacterial infections, and to prevent initial or recurrent attacks of rheumatic fever in patients allergic to penicillin.
Erythromycin oral tablets has a market value of more than $49 million, according to IQVIA data as of January 2021.